The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial
- PMID: 14583106
- DOI: 10.1089/154099903322404302
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial
Abstract
Purpose: Vaginal microbicides will provide a woman-initiated prevention strategy that could substantially reduce rates of HIV infection. The acceptability of microbicides will greatly influence the use and, hence, effectiveness of such products. In this study, the acceptability of an investigational microbicide, PRO 2000 Gel (Indevus Pharmaceuticals, Inc., Lexington, MA), was assessed, and women's opinions about microbicides and their potential for real world use were gathered.
Methods: Quantitative and qualitative data were collected from 30 U.S. and 33 South African women. All sexually active HIV-uninfected women and all sexually abstinent HIV-infected women participating in this phase I clinical trial stated in a survey that they would use PRO 2000 Gel if they had reason to be concerned about HIV and the product were available. Qualitative data, however, provided insight into the nuances of acceptability ratings. Women rated product safety, ease of use, and positive effects on sexual pleasure among the most important characteristics of acceptable microbicides.
Results: Opinions regarding product leakage, contraceptive capability, and the ability to be used without partners noticing, as well as characteristics of the product itself, varied substantially based on the context of sex and perceptions of risk within each individual woman's life.
Conclusions: As microbicide development continues and the first investigational products move into efficacy trials, the needs and preferences of those women who constitute the potential users of microbicides become paramount. Providing woman-initiated microbicides that are safe, easy to use, and pleasurable will be key to the impact these products will have on the AIDS epidemic worldwide.
Similar articles
-
Re-framing microbicide acceptability: findings from the MDP301 trial.Cult Health Sex. 2010 Aug;12(6):649-62. doi: 10.1080/13691051003736261. Cult Health Sex. 2010. PMID: 20397079 Clinical Trial.
-
Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya.Sex Health. 2008 Dec;5(4):339-46. doi: 10.1071/sh08011. Sex Health. 2008. PMID: 19061553
-
Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.AIDS Behav. 2020 Feb;24(2):637-647. doi: 10.1007/s10461-019-02576-8. AIDS Behav. 2020. PMID: 31254190 Free PMC article. Clinical Trial.
-
Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.J Int AIDS Soc. 2015 Dec 21;18(1):20536. doi: 10.7448/IAS.18.1.20536. eCollection 2015. J Int AIDS Soc. 2015. PMID: 26700845 Free PMC article. Review.
-
Clinical development of microbicides for the prevention of HIV infection.Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374. Curr Pharm Des. 2004. PMID: 14754390 Review.
Cited by
-
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.AIDS Care. 2014;26(12):1521-5. doi: 10.1080/09540121.2014.938014. AIDS Care. 2014. PMID: 25285564 Free PMC article. Clinical Trial.
-
Release of tenofovir from carrageenan-based vaginal suppositories.Pharmaceutics. 2014 Jul 4;6(3):366-77. doi: 10.3390/pharmaceutics6030366. Pharmaceutics. 2014. PMID: 24999606 Free PMC article.
-
Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.Contraception. 2015 Dec;92(6):596-601. doi: 10.1016/j.contraception.2015.08.007. Epub 2015 Aug 11. Contraception. 2015. PMID: 26276246 Free PMC article.
-
Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories.BMC Womens Health. 2018 Oct 20;18(1):170. doi: 10.1186/s12905-018-0657-2. BMC Womens Health. 2018. PMID: 30342510 Free PMC article.
-
Preferred characteristics of vaginal microbicides in women with bacterial vaginosis.J Womens Health (Larchmt). 2009 Aug;18(8):1163-7. doi: 10.1089/jwh.2008.1067. J Womens Health (Larchmt). 2009. PMID: 19630538 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials